Marine bacteria to fight tough infections

January 8, 2014, University of Copenhagen

Aggressive infections are a growing health problem all over the world. The development of resistant bacteria is rampant and, in the United States, resistant staphylococci cause more deaths than AIDS on an annual basis. Researchers from the University of Copenhagen are studying a new form of treatment based on marine bacteria. The results have been published in PLOS ONE.

Staphylococci have been a big problem for hospitals all over the world since the 1940s and, for many years, the pharmaceutical industry has been able to develop to keep up with the emergence of the aggressive bacteria. However, from 1970 to 2000, virtually no new antibiotics have come on the market. Staphylococci are gaining in the race – resistance is growing, and treatment options are few. In short, doctors have been set back to the time before penicillin was mass produced.

Research performed in collaboration between the University of Copenhagen and the Technical University of Denmark (DTU) focus on a new form of treatment – so-called antivirulence therapy – based on producing Staphylococcus inhibiting compounds.

"The marine compounds effectively inhibit the ability of to form toxins and camouflage proteins that prevent our immune system from reacting to an infection. At the same time, marine compounds appear to paralyse a sophisticated communication system that provides staphylococci the opportunity to undertake a coordinated attack on the organism," says Anita Nielsen, PhD. She has published new results in PLOS ONE with Professor Hanne Ingmer from the Department for Veterinary Disease Biology at the University of Copenhagen's Faculty of Health and Medical Sciences.

In the United States, resistant staphylococci cause more deaths than AIDS on an annual basis. Antivirulence therapy protects the body's natural bacterial flora and disarms, so to speak, infectious staphylococci bacteria. In this way, the body's immune system potentially gets a chance to defend itself against infection – and, in the long term, this form of treatment can mean that patients experience fewer harmful side effects.

Potent compound from the Solomon Islands

The researchers have analysed compounds extracted from marine bacteria collected from all over the world on the Galathea 3 expedition, which took place from August 2006 until April 2007. One particular compound, Solonamid B, isolated from a marine bacterium found near the Solomon Islands, is of particular interest.

"Solonamid B inhibits the ability of staphylococci to produce various toxins that break down our blood cells. White in particular are important in this context, because they participate in the fight against invasive bacteria during an infection. When Solonamid B is added to bacteria, it reduces their toxin production so only a fifth of the die that would otherwise succumb to the staphylococci toxins," says Professor Hanne Ingmer.

It has required demanding laboratory work to analyse the compounds that can form the basis for antivirulence therapy in the future. Purification and identification of the Solonamid B used for the cell studies were undertaken in collaboration with DTU. Researchers at DTU extracted the compounds that researchers at University of Copenhagen subsequently tested biologically. Future experiments will show whether the antivirulence compounds also work in animals and human beings.

Explore further: Novel non-antibiotic agents against MRSA and common strep infections

Related Stories

Novel non-antibiotic agents against MRSA and common strep infections

September 12, 2012
Menachem Shoham, PhD, associate professor of biochemistry at Case Western Reserve University School of Medicine, has discovered novel antivirulence drugs that, without killing the bacteria, render Methicillin Resistant Staphylococcus ...

Now we know why old scizophrenia medicine works on antibiotics-resistant bacteria

May 17, 2013
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...

Rainforest plant combats multi-resistant bacterial strains

February 20, 2012
Aggressive infections in hospitals are an increasing health problem worldwide. The development of bacterial resistance is alarming. Now a young Danish scientist has found a natural substance in a Chilean rainforest plant ...

Recommended for you

Bioengineered soft microfibers improve T-cell production

January 18, 2018
T cells play a key role in the body's immune response against pathogens. As a new class of therapeutic approaches, T cells are being harnessed to fight cancer, promising more precise, longer-lasting mitigation than traditional, ...

Weight flux alters molecular profile, study finds

January 17, 2018
The human body undergoes dramatic changes during even short periods of weight gain and loss, according to a study led by researchers at the Stanford University School of Medicine.

Secrets of longevity protein revealed in new study

January 17, 2018
Named after the Greek goddess who spun the thread of life, Klotho proteins play an important role in the regulation of longevity and metabolism. In a recent Yale-led study, researchers revealed the three-dimensional structure ...

The HLF gene protects blood stem cells by maintaining them in a resting state

January 17, 2018
The HLF gene is necessary for maintaining blood stem cells in a resting state, which is crucial for ensuring normal blood production. This has been shown by a new research study from Lund University in Sweden published in ...

Magnetically applied MicroRNAs could one day help relieve constipation

January 17, 2018
Constipation is an underestimated and debilitating medical issue related to the opioid epidemic. As a growing concern, researchers look to new tools to help patients with this side effect of opioid use and aging.

Researchers devise decoy molecule to block pain where it starts

January 16, 2018
For anyone who has accidentally injured themselves, Dr. Zachary Campbell not only sympathizes, he's developing new ways to blunt pain.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Returners
1 / 5 (1) Jan 08, 2014
When Solonamid B is added to bacteria, it reduces their toxin production so only a fifth of the white blood cells die that would otherwise succumb to the staphylococci toxins,


Is the plan to use this as a topical gel in the affected area, or is it safe for oral use or injection? Is it safe and stable in the presence of other anti-bacteria agents; i.e. antibiotic ointment?

Very interesting nonetheless. I know various strains of Staph exist all over the world, including among animals, so I'm wondering if this is a defense mechanism of the organism to work against Staph.

Searching for "Eureka moment" cures among marine biology has become more common recently in the field of medicine. I suppose it's true that almost anything you can imagine already exists somewhere in the ocean, and quite many things one might not imagine, so I guess finding stuff through "random sampling" is just as well as scratching your head and trying to design new designer molecules in the lab from scratc

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.